Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12609001011279
Ethics application status
Approved
Date submitted
30/01/2009
Date registered
23/11/2009
Date last updated
13/08/2012
Type of registration
Prospectively registered
Titles & IDs
Public title
The burden of subclinical synovial inflammation in gout
Query!
Scientific title
An observational pilot study to assess the burden of subclinical synovial inflammation in gout
Query!
Secondary ID [1]
1142
0
nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Gout
4255
0
Query!
Condition category
Condition code
Musculoskeletal
4477
4477
0
0
Query!
Other muscular and skeletal disorders
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Routine drug therapy as perscribed by the treating physician. This may include agents to treat acute gout including Non steroidal anti inflammatory drugs, colchicine and corticosteroids, and prophylactic agents including allopurinol and probenicid. Each Participant will be observed at two time points, once during acute gout and onbce during intercritical gout. The timing of observation will depend on the natural history of the disease in each patient, however it would be presumed that both observations would occur within a 12 month period. Patients will be reassessed at 2 years with repeat radiographs of joints imaged at baseline ( for clincal reasons) to look for progression of damage
Query!
Intervention code [1]
3977
0
Treatment: Drugs
Query!
Comparator / control treatment
Not applicable as this is an observational study
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
5357
0
Ultrasound detected synovitis
Query!
Assessment method [1]
5357
0
Query!
Timepoint [1]
5357
0
The primary outcome will be determined when the study subject has completed 2 study visits. These will be one visit during an intercritical period and one visit during a critical period of gout. The timepoints at which outcomes will be assessed depends on the clincial status of the patients, will be variable and cannot be specified a-priori, however we envisage all patients will complete alla ssessments within a 12 month period from enrolment in the study.
Query!
Primary outcome [2]
287741
0
Samples of serum and urine will be analysed for appropriate biomarkers of synovial inflammation, including hylauronan, C telopeptide of type 11 collagen, and RAGE using ELISA kits
Query!
Assessment method [2]
287741
0
Query!
Timepoint [2]
287741
0
The primary outcome will be determined when the study subject has completed 2 study visits. These will be one visit during an intercritical period and one visit during a critical period of gout. The timepoints at which outcomes will be assessed depends on the clincial status of the patients, will be variable and cannot be specified a-priori, however we envisage all patients will complete alla ssessments within a 12 month period from enrolment in the study
Query!
Secondary outcome [1]
298754
0
The relationship between synovial inflammation detected at baseline and progression of Xray changes at 2 years
Query!
Assessment method [1]
298754
0
Query!
Timepoint [1]
298754
0
2 years
Query!
Eligibility
Key inclusion criteria
1. A diagnosis of gout based on clinical presentation ( history, examination and biochemical tests)
2. Ability to give informed consent
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1.Inability to give informed consent
2.Contraindication or unwillingness to undergo an ultrasound scan
3.Diagnosis of other inflammatory joint disorder, such as rheumatoid arthritis
Query!
Study design
Purpose
Natural history
Query!
Duration
Longitudinal
Query!
Selection
Defined population
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
1/01/2010
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
30
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Funding source category [1]
4434
0
University
Query!
Name [1]
4434
0
University of Western Australia
Query!
Address [1]
4434
0
Faculty of Medicine, Dentistry and Health Sciences, MBDP 500, 35 Stirling Highway, Crawley WA 6009
Query!
Country [1]
4434
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
Royal Perth Hospital
Query!
Address
Wellington Street
Perth,
Western Australia,
6000.
Query!
Country
Australia
Query!
Secondary sponsor category [1]
3995
0
None
Query!
Name [1]
3995
0
Query!
Address [1]
3995
0
Query!
Country [1]
3995
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
6486
0
Royal Perth Hospital Ethics Committee
Query!
Ethics committee address [1]
6486
0
Royal Perth Hospital, Wellington Street Perth, Western Australia, 6000
Query!
Ethics committee country [1]
6486
0
Query!
Date submitted for ethics approval [1]
6486
0
04/02/2009
Query!
Approval date [1]
6486
0
21/05/2009
Query!
Ethics approval number [1]
6486
0
EC 2009/020
Query!
Summary
Brief summary
An observational pilot study to assess the burden of subclinical gout during an acute attack and during an intercritical period through asssessment of ultrasound detected synocial hypertrophy and urine hyaluronan
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
29235
0
Query!
Address
29235
0
Query!
Country
29235
0
Query!
Phone
29235
0
Query!
Fax
29235
0
Query!
Email
29235
0
Query!
Contact person for public queries
Name
12482
0
Dr Priya Chowalloor
Query!
Address
12482
0
Rheumatology Department
Royal Perth Hospital,
Wellington Street
Perth,
Western Australia,
6000
Query!
Country
12482
0
Australia
Query!
Phone
12482
0
+61 8 9224 2244
Query!
Fax
12482
0
Query!
Email
12482
0
[email protected]
Query!
Contact person for scientific queries
Name
3410
0
Helen Keen
Query!
Address
3410
0
Rheumatology Department
Royal Perth Hospital,
Wellington Street
Perth,
Western Australia,
6000
Query!
Country
3410
0
Australia
Query!
Phone
3410
0
+61 8 9224 2244
Query!
Fax
3410
0
Query!
Email
3410
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF